FrostPharma has entered an agreement with STEROP, bringing 5 additional products to the current FrostPharma portfolio. The deal encompasses commercial rights, including distribution and market authorization rights for the included products.
“FrostPharma has showed a very strong development since the start in 2017 and we have continuously reinvested the profits to build the portfolio with value-added products, allowing us to bring beneficial treatment options across multiple disease areas to our markets. With this agreement we will further strengthen the long-term outlook for FrostPharma’s future growth in all the Nordic countries.”, says CEO Cecilia Bröms-Thell.
The expected sales for the products included in the agreement with STEROP will contribute significantly to the top-line growth of FrostPharma already in the near-term perspective.
About FrostPharma AB:
FrostPharma is an entrepreneurial Swedish pharmaceutical company specializing in the commercialization of value-added products.
Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, throughout the Nordic countries and beyond. The key to our success is using our extensive in-house commercialization competence to match specific patient and health care needs with relevant products.
STEROP is a Belgian pharmaceutical group with the ambition to be a global leading player in the field of essential medicines and innovative products.